about
Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.Growth deficiency in oculodigitoesophagoduodenal (Feingold) syndrome--case report and review of the literature.Blood pressure centiles for Great Britain.Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trialDevelopment of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2-16 Years.Healthcare Resource Utilization and Costs Associated with Ketosis Events in Pediatric and Adult Patients with Type 1 Diabetes Mellitus in the UK.Short-term growth in children with congenital adrenal hyperplasia.Post-traumatic stress symptoms in mothers of very low birth weight infants 2-3 years post-partum.The relationship between stature, growth, and short-term changes in height and weight in normal prepubertal children.Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus.The disparate psychological and social support available for parents in UK tertiary-level neonatal unitsRegular fluctuations in growth hormone (GH) release determine normal human growthShort-term changes in growth and urinary growth hormone, insulin-like growth factor-I and markers of bone turnover excretion in healthy prepubertal childrenInfradian rhythms in urinary growth hormone excretionIntravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestationsHow is money spent on children's services?Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistanceCost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UKThe rate of hyperglycemia and ketosis with insulin degludec-based treatment compared with insulin detemir in pediatric patients with type 1 diabetes: An analysis of data from two randomized trialsClinical Use of Degludec in Children and Adolescents with T1D: A Narrative Review with Fictionalized Case Reports
P50
Q27026774-7B4E0BD9-7333-4AC1-8341-6FEC11D1F2C7Q35549468-BE9C0CBB-81DE-4531-BDC9-0D2D9C0FD0B2Q36148001-790F825C-B4A3-4FFB-A13F-F6667ACCEC44Q36155254-B734AA93-F6DE-4934-AB04-232DC19BD0BCQ36629167-4E3FF362-17C7-4ACA-B286-4841A1627F71Q37427287-B764F40D-E0F4-42E2-A359-59BF240B0010Q42371750-233132EE-B6C2-4EB0-91FC-20199A946684Q43972383-C539B039-F848-40EC-AE91-EA5AB1D5C779Q47190589-FF9D14EF-9B72-4000-9D9C-8DCD628C631DQ47274408-4B7613DC-1BA7-457B-BF8D-B9560622D553Q51376686-9E2DF6D3-EE8C-4CA0-8A0C-E03B7D39AF3EQ57954729-67763FE4-799F-46A6-BA6D-CB12F694BFEAQ58852182-C8946916-C421-4525-9B5F-CC526436E0B3Q62750319-92B7D71F-FFC8-4E5E-B669-9C7DE588F074Q70871273-31883C1F-C78D-46AA-BC40-48F946867677Q79157823-3CCB3175-B330-4FE2-82AC-68D1665ACFFBQ80473612-2BC73989-8A18-4027-AB3D-0CB9C0A20555Q80543262-65522385-6B73-478A-9A88-C0F29D527A3EQ90206853-0D8D3C59-8406-43D4-AA38-50ABAA01E3B9Q91151569-971551AD-0970-402F-9890-CFE0FAC23E11Q92674802-1D9325DC-E69A-4BD5-926E-33C49BDFED3D
P50
description
researcher ORCID ID = 0000-0001-7925-625X
@en
wetenschapper
@nl
name
Nandu Thalange
@ast
Nandu Thalange
@en
Nandu Thalange
@es
Nandu Thalange
@nl
type
label
Nandu Thalange
@ast
Nandu Thalange
@en
Nandu Thalange
@es
Nandu Thalange
@nl
prefLabel
Nandu Thalange
@ast
Nandu Thalange
@en
Nandu Thalange
@es
Nandu Thalange
@nl
P106
P1153
26428175600
P31
P496
0000-0001-7925-625X